SKAN Group stock
SKAN.SWSIXSKAN Group AG, HealthcareISIN CH0013396012
72Score 72 out of 100, Strong
Price and trend
76 / 100
Price history
+41% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 31).
The price is 9.0% below its 52-week high. Largest decline in 5 years: 56% (November 2021 to April 2026).
Chart figures for advanced users
- SMA 50$83.58
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$68.23
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)31
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$48.68
- The lowest closing price of the last twelve months.
- Resistance$91.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- SKAN Group AG belongs to the Medical (Instruments & Supplies) industry (Switzerland) and, with a market value of $1.88B, is number 36 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $401.67M (down 7.7% year on year) and earnings of $19.61M (down 58.1%).
- For fiscal 2026, analysts expect on average revenue of $477.41M (up 18.9%) and adjusted earnings per share of $1.69.
Show more
- MEQIRI Score 72 out of 100 (Strong): rank 106 of 714 in Healthcare, median 53.
- The P/E is 52 (Medical (Instruments & Supplies) median 34.8, own median of recent years 73.3).
- Our model puts fair value at $57.06, with the price 47% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 22.6% a year through 2028 (estimates from 2 analysts).Growth 86
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 78
Weaknesses
- DilutionShare count up 115% since 2020.Capital allocation 48
- Above fair valuePrice 47% above the fair value of $57.06.Valuation 26
- Margin fallingOperating margin 7.6%, average of the prior years 10.6% (to 2024).
Its standout strengths are growth and momentum, while capital allocation and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 71 to 72.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $43.89 and expensive above $81.52 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $58.24 (cash-flow model) and $55.88 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 5.6%. At 6.6% the fair value would be $51.71, at 4.6% it would be $65.13.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 9.4% on the twelve months before. Revenue has grown strongly since 2012, at around 40% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 69%, operating 8%, net 5%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 23 Mar 2027in 131 days
- Last reported
- 18 Aug 2026EPS reported $0.26
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.690.0%
- Revenue
- $477.41M0.0%
- Earnings per share
- $2.220.0%
- Revenue
- $551.19M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at SKAN Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 72
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- AzentaAZTA $2.14B52
- Bonesupport HoldingBONEX.ST $2.1B72
- DENTSPLY SIRONAXRAY $1.95B48
- Kestra Medical TechnologiesKMTS $1.88B45
- LeMaitre VascularLMAT $1.81B70
- STAAR SurgicalSTAA $1.34B45
- GerresheimerGXI.DE $1.23B48
- Safilo GroupSFL.MI $952.24M61
ETFs that hold SKAN Group
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree Europe SmallCap Dividend UCITS ETFWTES | 0.14% | 0.38% | €86.74M |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.07% | 0.23% | €319.31M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.07% | 0.30% | €3.43B |
Show 5 more
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.03% | 0.45% | €1.53B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.02% | 0.30% | €810.11M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.00% | 0.39% | €1.47B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.